# Effect of Hepatic Impairment on the Pharmacokinetics, Safety and Tolerability of BAY1002670 (Vilaprisan)

> **NCT03092999** · PHASE1 · COMPLETED · sponsor: **Bayer** · enrollment: 36 (actual)

## Conditions studied

- Leiomyoma

## Interventions

- **DRUG:** Vilaprisan (BAY1002670)

## Key facts

- **NCT ID:** NCT03092999
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-03-28
- **Primary completion:** 2017-07-17
- **Final completion:** 2017-07-17
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2017-08-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03092999

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03092999, "Effect of Hepatic Impairment on the Pharmacokinetics, Safety and Tolerability of BAY1002670 (Vilaprisan)". Retrieved via AI Analytics 2026-07-09 from https://api.ai-analytics.org/clinical/NCT03092999. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*